RGEN (Repligen) Cyclically Adjusted Revenue per Share: $9.98 (As of Mar. 2026)


RGEN Repligen Corp RGEN
84 GF Score
Price $137.50
GF Value $176.53
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Cyclically Adjusted Revenue per Share?

Repligen RGEN -1.67% 84 Cyclically Adjusted Revenue per Share is $9.98 as of Mar. 2026. GuruFocus rates RGEN with a GF Score™ of 84/100 and a GF Value™ of $176.53 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Repligen's adjusted revenue per share for the three months ended in Mar. 2026 was $3.428. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $9.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Repligen's average Cyclically Adjusted Revenue Growth Rate was 14.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 22.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 23.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Repligen was 30.20% per year. The lowest was -30.90% per year. And the median was 18.60% per year.

As of today (2026-07-09), Repligen's current stock price is $137.50. Repligen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $9.98. Repligen's Cyclically Adjusted PS Ratio of today is 13.78.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Repligen was 79.23. The lowest was 10.31. And the median was 24.37.


Repligen  (NAS:RGEN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Repligen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=137.50/9.98
=13.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Repligen was 79.23. The lowest was 10.31. And the median was 24.37.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Repligen Cyclically Adjusted Revenue per Share Related Terms


Repligen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Repligen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen Cyclically Adjusted Revenue per Share Chart

Repligen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.76 6.22 7.27 8.36 9.56

Repligen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.69 9.00 9.32 9.56 9.98

RGEN vs ATR, AVTR, TFX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Repligen's Cyclically Adjusted PS Ratio falls into.


RGEN
84GF Score
Repligen Corp RGEN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repligen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Repligen's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.428/330.2130*330.2130
=3.428

Current CPI (Mar. 2026) = 330.2130.

Repligen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.854 241.018 1.170
201609 0.719 241.428 0.983
201612 0.745 241.432 1.019
201703 0.890 243.801 1.205
201706 0.925 244.955 1.247
201709 0.859 246.819 1.149
201712 0.936 246.524 1.254
201803 1.011 249.554 1.338
201806 1.060 251.989 1.389
201809 1.081 252.439 1.414
201812 1.117 251.233 1.468
201903 1.310 254.202 1.702
201906 1.441 256.143 1.858
201909 1.340 256.759 1.723
201912 1.310 256.974 1.683
202003 1.433 258.115 1.833
202006 1.641 257.797 2.102
202009 1.759 260.280 2.232
202012 1.952 260.474 2.475
202103 2.512 264.877 3.132
202106 2.870 271.696 3.488
202109 3.107 274.310 3.740
202112 3.225 278.802 3.820
202203 3.509 287.504 4.030
202206 3.661 296.311 4.080
202209 3.503 296.808 3.897
202212 3.275 296.797 3.644
202303 2.899 301.836 3.172
202306 2.799 305.109 3.029
202309 2.480 307.789 2.661
202312 2.985 306.746 3.213
202403 2.710 312.332 2.865
202406 2.815 314.175 2.959
202409 2.765 315.301 2.896
202412 2.989 315.605 3.127
202503 2.991 319.799 3.088
202506 3.227 322.561 3.304
202509 3.340 324.800 3.396
202512 3.492 324.054 3.558
202603 3.428 330.213 3.428

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $9.98 mean?
Repligen (RGEN) has a Cyclically Adjusted Revenue per Share of $9.98 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Repligen and its competitors.
Is Repligen's Cyclically Adjusted Revenue per Share too high?
Repligen's current Cyclically Adjusted Revenue per Share is $9.98. Overall, Repligen has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Cyclically Adjusted Revenue per Share compare to ATR and AVTR?
Repligen's Cyclically Adjusted Revenue per Share of $9.98 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Repligen and its competitors. Repligen's current Cyclically Adjusted Revenue per Share is $9.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $176.53, compared to a current price of $137.50 — trading 22.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $9.98. Repligen's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Repligen (RGEN), the current Cyclically Adjusted Revenue per Share is $9.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $137.50 is trading 22.1% below its estimated GF Value™ of $176.53. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Cyclically Adjusted Revenue per Share: $9.98
  • GF Value™: $176.53 vs. price of $137.50 (22.1% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
84GF Score

Get the complete analysis for RGEN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$137.50
Price
$176.53
GF Value